CombiGene gears up for clinical studies and expanded pipeline

CombiGene’s report for the third quarter is primarily defined by the important initiation of GMP production of drug candidate CG01 as an epilepsy treatment. However, it is the news that came right after the Q3 period that stands out the most – the exclusive, global licensing agreement for CG01 that CombiGene entered with American Spark Therapeutics, an agreement that changes the gene therapy company at its core. BioStock summarises the autumn for the company, as it approaches its first clinical trial.